The Surefire Vaccine Winner Following AstraZeneca's COVID-19 Trial Pause

On Saturday, AstraZeneca received a green light from U.K. regulators to resume the clinical trial. However, as pit stops do with car racing, this temporary delay changes the dynamics in the coronavirus vaccine race to some extent. And I think that there's one surefire vaccine winner following AstraZeneca's COVID-19 trial pause -- Pfizer (NYSE:PFE).